CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade

The promise of immunotherapy to induce long-term durable responses in conventionally treatment resistant tumors like glioblastoma (GBM) has given hope for patients with a dismal prognosis. Yet, few patients have demonstrated a significant survival benefit despite multiple clinical trials designed to...

Descripción completa

Detalles Bibliográficos
Autores principales: von Roemeling, Christina, Yegorov, Oleg, Yang, Changlin, Klippel, Kelena, Russell, Rylynn, Trivedi, Vrunda, Bhatia, Alisha, Doonan, Bently, Carpenter, Savannah, Ryu, Daniel, Grippen, Adam, Futch, Hunter, Ran, Yong, Hoang-Minh, Lan, Weidert, Frances, Golde, Todd, Mitchell, Duane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680939/
https://www.ncbi.nlm.nih.gov/pubmed/38014191
http://dx.doi.org/10.21203/rs.3.rs-3463730/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680939/
https://www.ncbi.nlm.nih.gov/pubmed/38014191
http://dx.doi.org/10.21203/rs.3.rs-3463730/v1

Ejemplares similares